Global Circulating Tumor Cell (CTC) Diagnostics Market Research Report 2022: Advantages Offered, by Non-invasivene Appr...
Mar 11, 2022
News provided by
Share this article
Share this article
The scope of this study involves clinical testing, prognostic and monitoring markets for CTCs in cancer. The report also includes the clinical research segment as well as currently approved CTC tests and their markets. By cancer type, the global market for circulating tumor cells diagnostics has been segmented into breast cancer, colorectal cancer and prostate cancer. The fast growth rate of the colorectal cancer segment is attributed to rapid rise in the incidence of colorectal cancer, especially young adults. The growing prevalence of cancer, as circulating tumor cells find their applications in the diagnosis of cancer and precision management; advancements in technologies such as NGS and immunofluorescence; and growing awareness about the novel diagnostic methods for cancers are all major factors that will boost market growth. Reasons for Doing this Study
This study was conducted to provide detailed information regarding new developments, prognostic and clinical research testing for circulating tumor cells. There is an increasing need for new and innovative technologies in this area. This industry is experiencing tremendous growth; the use of new prognostic technologies based on circulating tumor cells has increased in the past few years. This study will increase awareness of current and emerging technologies and practices for cancer and cancer research, especially for prostate, breast and colorectal cancers. The regulatory environment, current technologies, new technologies, cancer incidence, market projections and market share, along with the latest trends and new developments in this area, are included to support the clinical testing market. This report discusses some of the major drivers and restraints in the market for circulating tumor cells diagnostics, and it surveys the competitive landscape as well as the key players' strategies and performances. The discussion is focused on the major market players, trends in product launches, collaborations, and mergers and acquisitions. The report also includes company profiles of major vendors that include a company overview, key product offerings, financial statistics and recent developments. The report provides insights on market shares and upcoming regional demand for circulating tumor cells diagnostics. Some of the major market players discussed in the report are Qiagen N.V., Biocept Inc., Greiner Bio One International GmbH, Precision Medicine Group LLC and Menarini Silicon Biosystems. For market estimates, data have been provided for the 2020 as the base year, with forecasts for 2021 through 2026. Projected and forecasted revenue values are in constant U.S. dollars that have not been adjusted for inflation. Report Includes
An up-to-date review and analysis of the global markets for circulating tumor cell (CTC) diagnostics
Analyses of the global market trends, with data from 2019-2021, and projections of compound annual growth rates (CAGRs) through 2026
Highlights of the upcoming market opportunities in the CTC diagnostics industry, and areas of focus to forecast this market into various segments and sub-segments
Evaluation and forecast the global CTC diagnostics market size, forecasted growth trends, and corresponding market share analysis by cancer type, technology, application, and region
In-depth information concerning market drivers and challenges, latest technologies, breakthrough innovations, costs and benefits of CTC enrichment techniques, regulatory concerns, and clinical trials
Statistical information (facts and figures) on cancer incidence and prevalence, global cancer related deaths, and new cases of cancer by type in the United States
Review of recent industry trends, value chain analysis, competitive landscape, and COVID-19 implications within the marketplace
Descriptive company profiles of the leading global players, including Bio-Techne Corp., Biocept Inc., Greiner Bio-One International GmbH, Precision Medicine Group LLC, Menarini Silicon Biosystems, and Qiagen N.V.
Key Topics Covered: